Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on Novemb...(number is 60186931. About Vanda Pharm...),Health
Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
Date:10/30/2007
number is 60186931.
About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder, and has recently submitted an NDA to the FDA for the treatment of schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Company Contact:
Steven A. Shallcross
Senior Vice President & CFO
Vanda Pharmaceuticals Inc.
(240) 599-4500
steven.shallcross@vandapharma.com
'/>"/>
| SOURCE Vanda Pharmaceuticals Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
(Date:7/9/2008)...Renowned oncology researcher Dr. Daniel Von Hoff, ...Advisory Board, provides an in-depth look at "... trial design that creates rapid accrual rates, su...ings, enthusiasm from investigators and patients, ...nterview is available for download from Medelis, a...
(Date:7/9/2008)...9 /PRNewswire/ -- Tricom Document Management,(Tric...gement of legacy and,current documents for a globa...fic Data Centers, Inc. (PDC), a data processing bu...ents so that they can better focus on their,core c...he latest technological advances and,state-of-the-...
(Date:7/9/2008)...f uKarma,s vertical integration strategy and will,...lth and wellness brands, LOS ANGELES, July 9 /PRN...etin Board: UKMA), a lifestyle multimedia and cons...and personal development, announced today the,firs...a in October, 2008., Xflowsion, with its revoluti...
(Date:7/9/2008)...Contributing Editor, Judy Bachrach Launches Newly,... Terminally Ill and Those ...wire/ -- (ZealousPR) -- Today, http://www.thechec...n for,the terminally ill and those who are close t...new easily accessible FORUM for readers to discuss...
Breaking Medicine News(10 mins):Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 3Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2Health News:Online Advice Column Receives Critical Acclaim; Baby Boomers Found Resourceful During Crisis 2[0] Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit [0] Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc.[0] uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel[0] Online Advice Column Receives Critical Acclaim; Baby Boomers Found Resourceful During Crisis
...experts have revealed that female foeticide is inc... mobile population of India. // The educated peopl...th, and poverty is not the only reason for these s...f selective abortions being made illegal in the co...
...hers belonging to the Yale School of Medicine have...regnant women are concerned can be diagnosed throu...ion in amniotic fluid. The chances of a premature ...ed through this process, according to the research...
... we know about the connection between age factor a...have found new proof that might establish this con...ng a study of baboons, it was discovered that as t...ncreased presence of old cells. It is well known t...
... from Pennsylvania school of medicine have found t...of severe stenosis or narrowed arteries in head ar.../ The result of the study conducted by Professor S...lished in the Journal Circulation. This new diag...
Other Medicine News:Health News:Link between Old Cells and Ageing probed 2(Date:7/9/2008)... Research Has Set National Safety Standards, ...swire-USNewswire/ -- In a congressional,hearing Se...discussed the,safety and importance of the researc...Affairs (VA) as well as an absolute commitment to ...single veteran would feel improperly,treated or mi...
(Date:7/9/2008)... SAN DIEGO, July 9 /- ... announced positive results from a multiple-ascend...uate the compound,s safety,pharmacokinetics and p...overed oral drug candidate intended for the treatm...tions., The Phase 1b trial was a randomized, doub...
(Date:7/8/2008)... MAIDENHEAD, England, July 8 /PRNewswire-Firs...ldren Against the Leading,Vaccine-Preventable Caus...countries of Cyprus, Hungary, the Kingdom of,Bahra...n for announcing,their decisions to routinely immu...al disease by adding PREVENAR(TM) PCV7 (Pneumococc...
(Date:7/8/2008)... GLP-1 Has Potential to Treat Type 2 Diabetes U... Technology, CEDAR KNOLLS, N.J., July 8 /PR.... (Nasdaq: EMIS ) today announced findings from a...-1 peptide safely and effectively.,The study used ...Eligen(R),technology, and was conducted at Univers...
Breaking Medicine Technology:Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules 2Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules 3Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Benchmarking Study Report on Sales Performance Management 21730 1Benchmarking Study Report on Sales Performance Management 21730 2Consumers Urged to Avoid Raw Milk and Raw Milk Products 21727 1Derma Sciences CEO ED Quilty Discusses Company on BNN 21725 1Derma Sciences CEO ED Quilty Discusses Company on BNN 21725 2Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 1Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 2Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 3[0] Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus[0] Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis[0] Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules[0] Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
...tudy evaluating a clinically relevant model of,nor...gent capable,of abrogating the cytotoxic effect of...d OPTISOME(tm) agent was generally well,tolerated ...ent,profile similar to conventional vincristine , ...EWSWIRE) --,Hana Biosciences (Nasdaq:HNAB), a biop...
..., NJ – June 4, 2007 – Genta,Incorporat...sults,from a Phase 2 clinical trial of its markete..., plus rituximab (Rituxan®;,Genentech/IDEC) an...ctory non-Hodgkin’s lymphoma (NHL). The data...can Society of Clinical,Oncology (ASCO) in Chicago...
Other Medicine Technology:Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5The Snellen chart remains to most popular chart design among clinicians. A range of different optotypes can be displayed in snellen format including British, sheridan-gardner, landolt Cs, tumbling Es
The PacScan 300AP is a portable, combination A-scan and pachymeter which provides easy-to-use touch screen operation. The combination of a high frequency, low noise probes and fast precise algorithms
Lightweight portable pachymeter, with compact LCD screen and optional printer. The Micropach 200P+ is extremely portable, weighing slightly more than 2 lbs (1 kg). The digital pachymeter provides a
16 segment Horizontal Prism bar provides 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45 PD. 4446 xx Horizontal Prism Bar.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |